Kyntra Bio Inc
Research Kyntra Bio Inc (KYNB) on Bullrun: market cap USD 24.78M, P/E 0.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKYNB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 24.78M
- P/E0.2
- Financial periodQ2 2026
- Revenue-USD 1.47M
- Net incomeUSD 11.97M
- Free cash flow-USD 3.99M
- Gross margin100.1%
Valuation Snapshot
latest market cap is USD 24.78M; P/E is 0.2.
Peer valuation comparison
Latest P/E is 0.19x versus a Healthcare sector median of 24.6x (99.2% below).
Latest P/E is 0.19x versus a United States median of 23.85x (99.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.44M | USD 183.45M | -USD 4.81M | 91.4% | 45.37 | USD 47.87M | USD 75.00M | -USD 30.04M |
| FY2024 | USD 29.62M | -USD 47.58M | -USD 138.27M | 47.5% | -11.89 | USD 50.48M | USD 73.09M | -USD 225.60M |
| FY2023 | USD 46.80M | -USD 284.23M | -USD 317.54M | 91.5% | -2.92 | USD 81.55M | USD 149.61M | -USD 204.17M |
| FY2022 | USD 140.73M | -USD 293.65M | -USD 149.67M | 85.6% | -3.14 | USD 155.70M | USD 89.89M | -USD 21.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 24.78M | 0.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 35.49M | 0.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 53.49M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 87.13M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.51B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.31B | n/a | n/a | n/a |
About Kyntra Bio Inc
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kyntra Bio Inc's market cap?
Kyntra Bio Inc's market capitalization is USD 24.78M.
What is Kyntra Bio Inc's P/E ratio?
Kyntra Bio Inc's price-to-earnings (P/E) ratio is 0.2.
What does Kyntra Bio Inc do?
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.